<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> are <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> group of clonal <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Various abnormalities in the immunoregulation system have been reported in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Most of studies were about lymphocytes in peripheral blood </plain></SENT>
<SENT sid="3" pm="."><plain>There weren't reports described lymphopoesis in the peripheral blood after reclassification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> according WHO </plain></SENT>
<SENT sid="4" pm="."><plain>We analyzed retrospectively subopulations of lymphocytes in bone marrow of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> recognized according to the WHO classification </plain></SENT>
<SENT sid="5" pm="."><plain>INVESTIGATED GROUP: There were 58 patients, 24 women and 34 men </plain></SENT>
<SENT sid="6" pm="."><plain>We recognized following subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: 5 pts with RA (8.5%), 22-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> (38%), 4-<z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e> (7%), 14-<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB1</z:e> (24%), 9-<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e> (15.5%), 3-<z:e sem="disease" ids="C0854809" disease_type="Neoplastic Process" abbrv="">MDS-U</z:e> (5%),1-5q- </plain></SENT>
<SENT sid="7" pm="."><plain>METHODS: Cell staining was performed in whole bone marrow during routine phenotyping with using following antibodies: anti-CD3, anti-CD4, anti-CD8, anti-CD16, anti-CD56, anti-CD19 </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the results have been statistically tested by using t-Student test and Spearmans correlation </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: There percentage of cells CD3+ was statistically larger, lymphocytes CD19+ statistically smaller, than in healthy in pts with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In analyzed subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB 1</z:e> and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e> we detected statistically larger percentage of cells: CD3+, CD3+CD4+, CD3+CD8+ and smaller lymphocytes CD 19+ percentage-than in <z:mpath ids='MPATH_458'>normal</z:mpath> BM </plain></SENT>
<SENT sid="11" pm="."><plain>Statistically larger percentage of cells CD3-CD16+CD56+ in subtype <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e> than <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB1</z:e> was only one statistically difference between subtypes <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB1</z:e> and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Following dependencies were found out in correlation's study: negative correlation between percentage of whole lymphocytes and celullarity of BM, percentage of lymphocytes, CD3+ cells, CD3+CD4+ cells and quantative of granulopoesis; positive correlation between percentage of CD3-CD16+CD56+ cells and changes in intensification of granulopoesis and percentage of CD3+CD8+ and quantitative of dyserythropoesis and changes in intensification megakariopoesis </plain></SENT>
<SENT sid="13" pm="."><plain>SUMMARY: Our studies show differences in percentage of whole lymphocytes in whole population of pts with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and supopulations: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB1</z:e> and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e> in comparison to healthy donors </plain></SENT>
<SENT sid="14" pm="."><plain>We showed relationship between: percentage of lymphocytes CD3+ and changes of intensification granulopoesis, CD3+CD8+ cells and dyserythropoesis and megakariopoesis </plain></SENT>
<SENT sid="15" pm="."><plain>Detected differences between subtypes <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB1</z:e> and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB2</z:e> in precemtage cells CD3CD16+CD56+ verified changes between these 2 new isolated by WHO subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>